Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
By Riccardo Lencioni, J. Llovet. Seminars in liver disease (Print), 2010
4,176 citations recorded by the source corpus.
The endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measurement of response rate in hepatocellular carcinoma (HCC) has become a controversial issue. The World Health Organization (WHO) criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Association for the Study of the Liver (EASL) to take into account treatment-induced tumor necrosis. Applying these guidelines, there was an association between response rate and outcome prediction. More recently, the Response Evaluation Criteria in Solid Tumors (RECIST) guideline was proposed as a method for measuring treatment response based on tumor shrinkage, which is a valuable measure of antitumor activity of cytotoxic drugs. This method was initially adopted by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for drug approval. However, anatomic tumor response metrics can be misleading when applied to molecular-targeted therapies or locoregional therapies in HCC. In 2008, a group of experts convened by the American Association for the Study of Liver Diseases (AASLD) developed a set of guidelines aimed at providing a common framework for the design of clinical trials in HCC and adapted the concept of viable tumor–tumoral tissue showing uptake in arterial phase of contrast-enhanced radiologic imaging techniques—to formally amend RECIST. These amendments conformed the AASLD-JNCI (Journal of the National Cancer Institute) guidelines and are summarized and clarified in the current article. They are referred to herein as the modified RECIST assessment (mRECIST). Further studies are needed to confirm the accuracy of this measurement compared with conventional gold standards such as pathologic studies of explanted livers.
Subfields: Hepatology, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/6703998f9dbdd132493a0dfe8d4c4b9189d5d0d8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
- J. Llovet
- Jordi Bruix1 , 2
- Riccardo Lencioni
- V. Mazzaferro
- Amit G. Singal
- Alejandro Forner1 , 2
- Andrew X. Zhu
- María E. Reig1 , 2
In Oncology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, methodology): “Consequently, a modification of the RECIST criteria was first proposed by a panel of experts [149], and further expanded [100].”
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “In the case of HCC surveillance, abnormal ultrasound results are either a newly detected focal lesion or a known hepatic lesion that enlarges and/or changes its echo pattern.(252)”
- Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. (2018, methodology): “Similar to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) (30), the LI-RADS algorithm is based on unidimensional measurements of the largest enhancing component of a treated tumor, excluding areas of nonenhancement (Fig 9), an approach that shows high reproducibility in response”
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020, neutral): “AST increased 20 (20) 4 (4) 5 (5) 11 (11) Proteinuria 20 (20) 9 (9) 7 (7) 4 (4) Asthenia 19 (19) 4 (4) 10 (10) 5 (5)”
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. (2016, methodology): “The primary efficacy objective was TTP by blinded central review, measured from the time of randomization until radiologic disease progression, according to modified response evaluation criteria in solid tumors (mRECIST), which takes into account reduction in viable tumor using contrast-enhanced rad”
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, methodology): “The investigators evaluated tumours in each treatment arm in accordance with mRECIST.(20,25) The liver 170 was examined with computed tomography or magnetic resonance imaging using a triphasic scanning 171 technique.”
- Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. (2014, neutral): “This approach is consistent with the incorporation of tumor enhancement as a measure of treatment response in newer imaging criteria (92).”
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, result): “In contrast, two enhancement criteria, the EASL criteria [539] and the modified RECIST (mRECIST) [540], have demonstrated superior efficacy for assessing treatment response and predicting survival outcome compared with the WHO criteria or RECIST [541–543].”
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, neutral): “[310,311] mRECIST has become the standard tool to assess radiological response after locoregional therapy for patients with early and intermediate stages of HCC, whereas both RECIST 1.1 and mRECIST are recommended for patients with advanced-stage HCC undergoing systemic therapy.”
- Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. (2013, methodology): “Accordingly, the RECIST criteria have been amended, at least for HCC [91], to stress that the imaging indicator of complete ablation is the disappearance of any previously visualized intralesional enhancement on CEUS.”